Abdul R Shaikh, National Cancer Institute, Bethesda, United States Sheri Schully*, National Cancer Institute, Bethesda, United States Muin Khoury*, National Cancer Institute, Bethesda, United States Bradford Hesse*, National Cancer Institute, Bethesda, United States Atul Butte*, Stanford University, Stanford, United States William Dalton*, Moffitt Cancer Center, Tampa, United States Track: Practice Presentation Topic: Collaborative biomedical research, academic / scholarly communication, publishing and peer review Presentation Type: Panel Submission Type: Panel Presentation Building: Joseph B. Martin Conference Center at Harvard Medical School Room: Auditorium Date: 2012-09-16 09:00 AM – 09:45 AM Last modified: 2012-09-12 Free Full Paper

If you are the presenter of this abstract (or if you cite this abstract in a talk or on a poster), please show the QR code in your slide or poster (QR code contains this URL).

Biomedicine is in the midst of a revolution, accelerated by high throughput and connective computing, that over time will transform the way medicine is practiced and research is conducted. Nowhere is this more evident than in oncology, where acceleration in the speed and capacity of genomic sequencing technologies is making it possible to draw increasingly more precise conclusions about the ways in which an individual’s genetic profile can be used to anticipate risk and target therapeutics. The goal is to enable an era of “4 P’s” medicine; medicine that will become increasingly more predictive, personalized, preemptive and participative over time. Admittedly, such a goal is an explicit attempt to take advantage of the impact of “disruptive technologies” in medicine to accelerate discovery and change the rules of clinical practice for patient-centered care. For example, creating predictive profiles of risk will require that individuals actively use the information made available to them in actionable ways to avoid risk for carcinogenic sensitivity while remaining vigilant to early warning. Developing a system of personalized medicine will require alterations in the ways in which data– for example, the whole-genome sequencing data for individual patients – may be stored and processed for decision making both within healthcare systems and without. Striving toward a preemptive stance, where early disease is averted before tissue damage or morbidity occur, will require an evolution of clinical information systems to support a lifespan of targeted vigilance and team-oriented situational awareness. Even more importantly, moving toward a participative orientation in medicine means turning the biomedical research sector away from its slow, 1-way data collection and translation model, to a many-to-many collaborative translation model in which scientists, practitioners, and patients share data and engage with each other to accelerate discovery and improve health outcomes at the population level.
To understand how these large trends in open medicine can be marshaled to accelerate movement toward 4 P’s medicine in an era of “big data,” this panel will focus on the design, development, and integration of informatics structures in oncology to encourage data sharing and innovation; to enumerate the actionable steps needed to enable a “learning healthcare system;” and to specify the requirements of an integrative systems approach to cancer control and prevention that will allow for the evolution of “collective intelligence” for disease and wellness in clinical medicine and population health.

Panel Organizers: Abdul Shaikh & Sheri Schully (co-chairs, NCI), Muin J. Khoury (NCI), Bradford Hesse (NCI)
Panelist 1: Bradford Hesse (National Cancer Institute) - Disease Complexity and P4 Medicine
Panelist 2: William Dalton (Moffitt Cancer Center) - Personalized Medicine and Cancer
Panelist 3: Atul Butte (Stanford) - Data-Driven Science and Personalized Medicine
Panelist 4: Muin J. Khoury (Centers for Disease Control and Prevention; NCI) - A Population Perspective on 4P Medicine
Discussant: Sheri Schully (NCI)